Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AARD vs BZFD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AARD Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 4–4 Matrix Metrics)

AARD Overall Winner 6-Pillar Tally: AARD 3 – 3 BZFD Matrix Metrics: AARD 4 – 4 BZFD

As of Nov 20, 2026, Aardvark Therapeutics, Inc. (AARD) is the stronger overall head-to-head candidate over BuzzFeed, Inc. (BZFD) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). AARD carries a Unified Composite Score of 45.9/100 (HOLD) at $0.92 (N/M Forward P/E, 0.0% operating margin), whereas BZFD carries 51.3/100 (HOLD) at $0.38 (N/M Forward P/E, -17.7% operating margin).

  • Composite vs. Pillar Nuance: While BZFD currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. AARD 45.9/100 HOLD), AARD captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -17.7% operating margin) and revenue trajectory (+0.0% vs. -43.8% YoY).
  • Technical & Structure Timing Caution: AARD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile BZFD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AARD vs BZFD
AARD NASDAQ Head-to-Head Winner
Aardvark Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.92
-7.74% 1D
Market Cap $21.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 3.84β · 284% Vol
Unified Composite Score
45.9 / 100 HOLD
Tech 35.0 Fund 54.0 Flow 68.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -36.6%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.25 · SMA50: $3.35
BZFD NASDAQ
BuzzFeed, Inc. Class A Common Stock
Communications Services, Nec
$0.38
+2.79% 1D
Market Cap $38.1M
TTM Revenue $150M
Forward P/E N/M
Beta / 30D Vol 2.52β · 192% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 55.0 Fund 52.0 Flow 60.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 25
RSI-14: 25.3 · SMA20: $0.65 · SMA50: $0.91

6-Pillar Scorecard Institutional Category Breakdown (AARD 3 – 3 BZFD)

Columns: Metric · AARD · BZFD
1. Valuation Multiples BZFD
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 0.5x
2. Growth & Scale AARD
Revenue Growth (YoY) +0.0% -43.8%
Earnings Growth (YoY) +0.0% -54.7%
TTM Revenue (USD) N/A $150M
Market Cap $21.9M $38.1M
3. Profitability & Quality AARD
Gross Margin N/A 40.5%
Operating Margin 0.0% -17.7%
Net Profit Margin 0.0% -48.0%
Return on Equity (ROE) -66.0% -123.0%
4. Balance Sheet & Cash Flow BZFD
Cash Generation (TTM) N/A -$39M
Cash Flow Margin N/A -26.2%
Net Cash / Leverage $73M Net Cash $39M Net Debt (1.18x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AARD
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 147.3% (26th %ile) 319.8% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BZFD
OpEx & R&D Intensity N/A 58.2% of Rev ($88M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Internet Content & Information Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AARD (4) vs BZFD (4)
Institutional Metric AARD BZFD Criterion Row Edge
Market Capitalization
Scale
$21.9M $38.1M Larger Scale BZFD
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -43.8% Higher Growth AARD
Operating Margin (TTM)
Profitability
0.0% -17.7% Higher Margin AARD
Net Profit Margin
Profitability
0.0% -48.0% Higher Margin AARD
Return on Equity (ROE)
Capital Efficiency
-66.0% -123.0% Higher ROE AARD
52-Week Range Position
Momentum
0% ($1–$17) 2% ($0–$2) Stronger Trend BZFD
Beta / 30D Volatility
Risk Regime
3.84β · 284% Vol 2.52β · 192% Vol Lower Realized Risk BZFD
Unified Institutional Score
Composite Signal
45.9 / 100 (HOLD) 51.3 / 100 (HOLD) Higher Composite BZFD
Trailing 12M Revenue (USD)
Operating Scale
N/A $150M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 40.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($73M Net Cash) -$39M ($39M Net Debt (1.18x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BZFD +15.33 pp
AARD: -76.64% · BZFD: -61.31%
3M Horizon BZFD +19.8 pp
AARD: -86.59% · BZFD: -66.79%
6M Horizon AARD +2.36 pp
AARD: -79.68% · BZFD: -82.04%
1Y Horizon BZFD +31.17 pp
AARD: -91.18% · BZFD: -60.01%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AARD vs BZFD. Trailing 12-month operating profitability (AARD 0.0% vs BZFD -17.7%) and valuation multiples (AARD N/M vs BZFD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AARD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-66.0% · N/M
BZFD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$150M
Gross Margin40.5%
Op. Margin-17.7%
ROE / Fwd P/E-123.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AARD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 147.3%
IV Percentile 26th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact AARD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BZFD BREAKDOWN
126d in phase · OBV NEUTRAL
Current IV 319.8%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BZFD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AARD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $21.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BZFD Moat Profile Cyclical / Execution-Driven Positioning
Internet Content & Information Operator
Competes within the Internet Content & Information value chain with $38.1M market capitalization and -17.7% operating margin.
OpEx & R&D Reinvestment 58.2% of Rev ($88M)
90D Engineering Disclosures 0 Published

Investor FAQ AARD vs BZFD Key Questions & Quantitative Answers

As of Nov 20, 2026, Aardvark Therapeutics, Inc. (AARD) is the stronger overall head-to-head candidate over BuzzFeed, Inc. (BZFD) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). AARD carries a Unified Composite Score of 45.9/100 (HOLD) at $0.92 (N/M Forward P/E, 0.0% operating margin), whereas BZFD carries 51.3/100 (HOLD) at $0.38 (N/M Forward P/E, -17.7% operating margin). Composite vs. Pillar Nuance: While BZFD currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. AARD 45.9/100 HOLD), AARD captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -17.7% operating margin) and revenue trajectory (+0.0% vs. -43.8% YoY). Technical & Structure Timing Caution: AARD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile BZFD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AARD leads the Growth & Scale pillar: AARD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with BZFD at -43.8% YoY revenue growth and -54.7% YoY earnings growth on $150M TTM revenue (40.5% gross margin, -17.7% operating margin). On trailing 12-month operating scale, AARD generates N/A in USD-normalized revenue versus $150M for BZFD. In operating R&D and SG&A reinvestment, AARD deploys N/A (0 90-day corporate R&D disclosures) versus 58.2% of Rev ($88M) (0 disclosures) for BZFD.

BZFD screens cheaper on headline valuation multiples. AARD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BZFD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (-26.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AARD (-66.0% ROE) versus BZFD (-123.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AARD carries 147.3% implied volatility (26th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.84β · 284% Vol realized risk). By comparison, BZFD carries 319.8% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.52β · 192% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.